The once-daily oral drug has been cleared under the Veozah brand name for moderate to severe vasomotor symptoms (commonly known as hot flashes) in menopausal women, becoming a non-hormonal ...

The company hasn’t given a timeline for those regulatory filings but will no doubt want to move quickly as it chases after Astellas, which claimed approval for NK 3 antagonist Veozah ...

Individuals are advised to discontinue use of the affected lots immediately and return the product to the point of purchase for replacement. Several lots of intravenous and subcutaneous immune ...